CANCER GENETICS, INC (51) | Business Finance (21)

Browse by Subcategory

Recent Contracts

Equity Distribution Agreement, dated April 8, 2022, by and between Vyant Bio, Inc. and Canaccord Genuity LLC (Filed With SEC on April 11, 2022)
Registration Rights Agreement dated March 28, 2022 between Lincoln Park Capital, LLC and Vyant Bio, Inc (Filed With SEC on March 30, 2022)
Purchase Agreement dated March 28, 2022 between Lincoln Park Capital, LLC and Vyant Bio, Inc (Filed With SEC on March 30, 2022)
Form of Stock Unit Award Agreement (Filed With SEC on April 5, 2021)
Form of Exchange Warrant dated March 30, 2021 (Filed With SEC on April 5, 2021)
Amended and Restated Underwriting Agreement, dated October 28, 2020, by and between Cancer Genetics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on November 2, 2020)
Exhibit 10.1 Note Purchase Agreement with Atlas Sciences (Filed With SEC on October 25, 2019)
Forbearance and Sixth Amendment to Amended and Restated Loan and Security Agreement, between Cancer Genetics, Inc. and Silicon Valley Bank, dated June 13, 2019 (Filed With SEC on August 19, 2019)
Form of Nonqualified Stock Option Grant Agreement (Filed With SEC on April 5, 2021)
Form of Securities Purchase Agreement, dated February 10, 2021 (Filed With SEC on February 16, 2021)
Form of Common Warrant (Filed With SEC on February 1, 2021)
Form of Registration Rights Agreement, dated January 28, 2021 (Filed With SEC on February 1, 2021)
Form of Securities Purchase Agreement, dated January 28, 2021 (Filed With SEC on February 1, 2021)
Form of Warrant Exchange and Amendment Agreement, dated as of November 20, 2020, by and between Cancer Genetics, Inc. and the Holders (Filed With SEC on November 20, 2020)
Exhibit 4.1 Promissory Note with Atlas Sciences (Filed With SEC on October 25, 2019)
Asset Purchase Agreement, dated July 5, 2019, by and among siParadigm, LLC and Cancer Genetics, Inc (Filed With SEC on August 19, 2019)
Secured Creditor Asset Purchase Agreement, dated July 15, 2019, by and among Interpace BioPharma, Inc., Cancer Genetics, Inc., Interpace Diagnostics Group, Inc. and Partners for... (Filed With SEC on July 19, 2019)
Promissory Note of Interpace BioPharma, Inc., dated July 15, 2019, in favor of Cancer Genetics, Inc (Filed With SEC on July 19, 2019)
Forbearance and Fifth Amendment to Amended and Restated Loan and Security Agreement with Silicon Valley Bank, dated January 16, 2019 (Filed With SEC on January 16, 2019)
Forbearance Agreement and Modification No. 4 to Loan and Security Agreement with Partners for Growth IV, L.P., dated January 16, 2019 (Filed With SEC on January 16, 2019)
Underwriting Agreement, dated January 9, 2019, by and between Cancer Genetics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on January 10, 2019)